North East and North Cumbria
ICS Formulary
 
back
6 Endocrine system
06-06-02 Denosumab

Denosumab Xgeva®
Formulary
  • Denosumab 70mg in 1ml (120mg) vial is approved for the prevention of skeletal-related events in adults with bone metastases from solid tumours in line with NICE 
    • Note: denosumab is not approved for therapy induced bone loss in non- metastatic prostate cancer (NICE).


  • North Cumbria only
    • New patients        Red
    • Exisiting patients  Green plus
Link  MHRA Drug Safety Updates: Denosumab
Link  NICE TA265: Bone metastases from solid tumours - denosumab: guidance

Red View adult BNF  View SPC online  View childrens BNF
Denosumab Prolia®
Formulary
  • Denosumab 60mg in 1ml solution in prefilled syringe is approved for use in the treatment of postmenopausal osteoporosis in line with NICE. Also approved for male patients who don't tolerate bisphosphonates or strontium ranelate. 
Link  NICE TA204: Osteoporotic fractures - denosumab
Link  MHRA Drug Safety Updates: Denosumab
Link  NENC Shared Care Protocol - Denosumab for primary and secondary prevention of fracture in women and men over the age of 50

Amber View adult BNF  View SPC online  View childrens BNF